Hemolytic uremic syndrome (HUS) is a complex and heterogeneous disorder characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. It is a leading cause of acute kidney injury and end-stage renal disease in children and adults. HUS can be broadly classified into two categories: typical and atypical.
Clinically, typical HUS presents with a classic prodrome of several days of watery diarrhea followed by bloody diarrhea (dysentery). Approximately five to ten days after the onset of diarrhea, the triad of HUS manifests: pallor (anemia), petechiae and bruising (thrombocytopenia), and decreased urine output (acute kidney injury). The prognosis for typical HUS is surprisingly favorable. With aggressive supportive care—including meticulous fluid and electrolyte management, blood transfusions, and often dialysis—the majority of children recover renal function completely. The mortality rate is low (1-5%) in the acute phase, and long-term sequelae, such as chronic kidney disease or hypertension, occur in a minority of patients. Crucially, typical HUS is not a recurrent disease; once a patient recovers from the acute infection, the syndrome does not return.
Hemolytic Uremic Syndrome (HUS) is a complex and potentially life-threatening condition characterized by a triad of symptoms: hemolytic anemia (destruction of red blood cells), thrombocytopenia (low platelet count), and acute kidney injury. typical vs atypical hemolytic uremic syndrome
| Feature | Typical HUS (tHUS) | Atypical HUS (aHUS) | | --- | --- | --- | | | Children < 5 years | Any age | | Cause | STEC infection | Genetic, autoimmune, infections, pregnancy | | Diarrhea | Common | Variable | | Recurrence | Rare | Common | | Outcome | Generally good | More severe, higher risk of ESRD |
Hemolytic Uremic Syndrome (HUS) is a complex group of rare blood disorders characterized by a triad of symptoms: (destruction of red blood cells), thrombocytopenia (low platelet count), and acute kidney injury (AKI) . While they share these core features, typical and atypical HUS differ significantly in their causes, progression, and treatment. Comparing Typical and Atypical HUS P102 Typical vs atypical hemolytic-uremic syndrome Hemolytic uremic syndrome (HUS) is a complex and
In summary, while typical and atypical HUS share a common histopathological appearance and clinical triad, they are fundamentally distinct entities. Typical HUS is an acute, self-limited, toxin-mediated condition triggered by a gastrointestinal infection, primarily affecting children and carrying a good prognosis with supportive care. Atypical HUS is a chronic, genetic disease of complement dysregulation, affecting all ages, characterized by a high risk of recurrence and progression to ESRD. The distinction is not merely academic; it is the pivot upon which accurate diagnosis, appropriate treatment (supportive care versus complement inhibition), and accurate prognosis hinge. For the clinician, suspecting HUS is only the first step; the crucial second step is to determine which face of the syndrome is staring back.
For aHUS, supportive care is insufficient. The therapeutic cornerstone is the blockade of terminal complement activation. The advent of eculizumab, a monoclonal antibody that inhibits the complement protein C5, has revolutionized the treatment of aHUS. This drug rapidly halts the thrombotic process, improves renal function, and prevents recurrence, including after transplantation. Without eculizumab or similar complement inhibitors, patients with aHUS face a lifetime of recurrent thrombotic crises and progressive organ failure. Clinically, typical HUS presents with a classic prodrome
Before the era of modern medicine, aHUS had a grim prognosis, with nearly 50% mortality or progression to end-stage renal disease (ESRD).
